<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04944992</url>
  </required_header>
  <id_info>
    <org_study_id>6024-001</org_study_id>
    <secondary_id>2020-005136-30</secondary_id>
    <secondary_id>MK-6024-001</secondary_id>
    <nct_id>NCT04944992</nct_id>
  </id_info>
  <brief_title>A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)</brief_title>
  <official_title>A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat&#xD;
      reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is&#xD;
      superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10%&#xD;
      with respect to mean relative reduction from baseline in liver fat content (LFC) after 24&#xD;
      weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2021</start_date>
  <completion_date type="Anticipated">December 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 13, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Relative Reduction from Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 weeks</measure>
    <time_frame>At Baseline and 24 weeks</time_frame>
    <description>LFC will be measured with liver images taken by MRI-PDFF and analyzed by BICR. The mean relative reduction (%) from baseline in LFC after 24 weeks of treatment will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experience an Adverse Event</measure>
    <time_frame>Up to Approximately 28 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinue Study Intervention Due to an Adverse Event</measure>
    <time_frame>Up to approximately 24 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Reduction from Baseline in LFC Measured by MRI-PDFF (evaluated by BICR) After 24 Weeks</measure>
    <time_frame>At Baseline and 24 weeks</time_frame>
    <description>LFC will be measured by liver images taken by MRI-PDFF and analyzed by BICR. The mean absolute reduction from baseline in LFC after 24 weeks of treatment will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change from Baseline in Body Weight After 24 weeks</measure>
    <time_frame>At Baseline and 24 Weeks</time_frame>
    <description>Body weight (kg) will be measured using a standardized, digital scale. The mean percent change from baseline in body weight after 24 weeks will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Total Cholesterol After 24 Weeks</measure>
    <time_frame>At Baseline and 24 Weeks</time_frame>
    <description>Fasting blood samples will be collected at baseline and after 24 weeks of treatment to assess mean change in total cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Non-High Density Lipoprotein-Cholesterol (non-HDL-C) After 24 Weeks</measure>
    <time_frame>At Baseline and 24 Weeks</time_frame>
    <description>Fasting blood samples will be collected at baseline and after 24 weeks of treatment to assess mean change in non-HDL-C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in High Density Lipoprotein-Cholesterol (HDL-C) After 24 Weeks</measure>
    <time_frame>At Baseline and 24 Weeks</time_frame>
    <description>Fasting blood samples will be collected at baseline and after 24 weeks of treatment to assess mean change in HDL-C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) After 24 weeks</measure>
    <time_frame>At Baseline and 24 Weeks</time_frame>
    <description>Fasting blood samples will be collected at baseline and after 24 weeks of treatment to assess mean change in LDL-C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Triglycerides (TG) After 24 Weeks</measure>
    <time_frame>At Baseline and 24 Weeks</time_frame>
    <description>Fasting blood samples will be collected at baseline and after 24 weeks of treatment to assess mean change in triglycerides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in Apolipoprotein B (apoB) After 24 Weeks</measure>
    <time_frame>At Baseline and 24 Weeks</time_frame>
    <description>Fasting blood samples will be collected at baseline and after 24 weeks of treatment to assess mean change in apoB.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Efinopegdutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efinopegdutide 20 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 2.4 mg from day 1 to week 3, 5.0 mg from week 4 to 7, and 10.0 mg from week 8 to 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Semaglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Semaglutide 1.34 mg/mL administered by injection once weekly for 24 weeks in a dose-escalation regimen: 0.25 mg from day 1 to week 3, 0.5 mg from week 4 to 7, and 1.0 mg from week 8 to 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efinopegdutide 20 mg/mL</intervention_name>
    <description>Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg</description>
    <arm_group_label>Efinopegdutide</arm_group_label>
    <other_name>MK-6024</other_name>
    <other_name>HM12525A</other_name>
    <other_name>JNJ-64565111</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 1.34 mg/mL</intervention_name>
    <description>Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg</description>
    <arm_group_label>Semaglutide</arm_group_label>
    <other_name>Ozempic®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver Fat Content (LFC) ≥10% as assessed by MRI-PDFF at time of screening.&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥25 kg/m² and ≤50 kg/m² at time of screening.&#xD;
&#xD;
          -  Stable weight (based on self-reporting) defined as ≤5% gain or loss of body weight for&#xD;
             at least 3 months before screening visit.&#xD;
&#xD;
          -  No history of Type 2 Diabetes Mellitus (T2DM) OR history of T2DM with an A1C ≤8.5% at&#xD;
             screening AND controlled by diet or a stable dose of metformin for the 3 months before&#xD;
             screening.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding, is not a woman of childbearing potential (WOCBP), or is a WOCBP and&#xD;
             agrees to follow contraceptive guidance during the study intervention period and for&#xD;
             at least 5 weeks after the last dose of study intervention.&#xD;
&#xD;
          -  Participants in Taiwan are eligible between the ages of 20 to 70 years of age&#xD;
             (inclusive).&#xD;
&#xD;
          -  Participants in South Korea are eligible between the ages of 19 to 70 years of age&#xD;
             (inclusive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of T1DM, diabetic ketoacidosis, or diabetes secondary to pancreatitis or&#xD;
             pancreatectomy.&#xD;
&#xD;
          -  Ongoing, inadequately controlled hypothyroidism or hyperthyroidism.&#xD;
&#xD;
          -  Personal or family history of medullary thyroid carcinoma or multiple endocrine&#xD;
             neoplasm type-2 syndrome.&#xD;
&#xD;
          -  Recent event (within 6 months prior to screening ) of congestive heart failure,&#xD;
             unstable angina, myocardial infarction, arterial revascularization, stroke, or&#xD;
             transient ischemic attack.&#xD;
&#xD;
          -  History or evidence of chronic liver disease other than NAFLD or Non-Alcoholic&#xD;
             SteatoHepatitis (NASH).&#xD;
&#xD;
          -  Known history of cirrhosis.&#xD;
&#xD;
          -  History of acute or chronic pancreatitis.&#xD;
&#xD;
          -  History of a bariatric surgical procedure or a known clinically significant gastric&#xD;
             emptying abnormality.&#xD;
&#xD;
          -  History of malignancy ≤5 years prior to screening, except for skin cancer or cervical&#xD;
             cancer.&#xD;
&#xD;
          -  Clinically active hematologic disorder.&#xD;
&#xD;
          -  Diagnosis of human immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Surgery requiring general anesthesia within 3 months before screening visit.&#xD;
&#xD;
          -  History of organ transplantation, except for corneal transplant.&#xD;
&#xD;
          -  Active diabetic proliferative retinopathy or a history of maculopathy.&#xD;
&#xD;
          -  Untreated obstructive sleep apnea.&#xD;
&#xD;
          -  History of treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist within&#xD;
             6 months before screening.&#xD;
&#xD;
          -  History of treatment with thiazolidinediones (ie, pioglitazone, rosiglitazone) within&#xD;
             6 months before screening.&#xD;
&#xD;
          -  Previous use (within 3 months before screening) or current use of prescription&#xD;
             weight-management medications or over-the-counter weight-loss medications or&#xD;
             therapies.&#xD;
&#xD;
          -  Treatment with systemic corticosteroid medication within 3 months before screening.&#xD;
&#xD;
          -  Current treatment with anticoagulants (eg, warfarin, heparin).&#xD;
&#xD;
          -  Inability to have an MRI-PDFF performed due to either severe claustrophobia, metallic&#xD;
             implant that prevents MRI-PDFF examination, or any other contraindication to MRI-PDFF&#xD;
             examination.&#xD;
&#xD;
          -  Previous or current history of significant alcohol consumption (average of 7 standard&#xD;
             drinks per week in females or 14 standard drinks per week in males) for a period of&#xD;
             more than 3 consecutive months in the 24 months before screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Catalina Research Institute, LLC ( Site 1939)</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>909-590-8409</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sweet Hope Research Specialty, Inc ( Site 1902)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-456-9062</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Floridian Clinical Research, LLC ( Site 1950)</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-330-9977</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sensible Healthcare, LLC ( Site 1903)</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-654-2724</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lucas Research, Inc ( Site 1930)</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>252-222-5700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute ( Site 1910)</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>817-471-1070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine-Advanced Liver Therapies ( Site 1960)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>731-798-1966</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at Texas Liver Institute ( Site 1920)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-253-3426</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc. ( Site 1906)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-949-0122</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital-Gastroenterology &amp; Hepatology ( Site 0204)</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61288903469</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre-Hepatology and Liver Transplant Medicine ( Site 0201)</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61882047544</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital F-ENDOCRINOLOGY-DIABETOLOGY ( Site 0401)</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d Or</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33380293453</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus-Liver disease unit ( Site 0704)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972 54 4746115</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center-Liver Unit ( Site 0703)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9778419</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>97226555116</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 0701)</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>97239377252</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center-The Liver Diseases Center ( Site 0700)</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972 3 5307179</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center-Gastroenterology and Liver Disease ( Site 0702)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972-527360787</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humanitas-Medicina interna ed Epatologia ( Site 0800)</name>
      <address>
        <city>Rozzano</city>
        <state>Lombardia</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390282247006</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Medicine ( Site 0804)</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390458126253</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Bucheon Hospital ( Site 1304)</name>
      <address>
        <city>Bucheon</city>
        <state>Kyonggi-do</state>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82326214911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital-Gastroenterolgy/Hepatology ( Site 1303)</name>
      <address>
        <city>Incheon</city>
        <zip>22332</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82328902548</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System ( Site 1305)</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>82222281988</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center-Gastroenterology/Internal Medicine ( Site 1302)</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-2-3410-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital ( Site 1300)</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+82-1577-9966</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avix Investigación Clinica, S.C. ( Site 0907)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>8115336632</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación y Gastroenterología ( Site 0902)</name>
      <address>
        <city>Cuauhtémoc</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5591974778</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital-Gastroenterology Research ( Site 1002)</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6433640135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital-Liver Research Unit ( Site 1003)</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6493074949</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Middlemore Clinical Trials ( Site 1000)</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+6492760044</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Przychodnie Medyczne ( Site 1105)</name>
      <address>
        <city>Torun</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48662062410</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Warszawa ( Site 1107)</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48502099937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Medical Research ( Site 1101)</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-156</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48327248013</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ID Clinic ( Site 1100)</name>
      <address>
        <city>Mysowice</city>
        <state>Slaskie</state>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48326161394</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Technologies of Medicine Clinic ( Site 1204)</name>
      <address>
        <city>Dzerzhinskiy</city>
        <state>Moskovskaya Oblast</state>
        <zip>140091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+74856979180</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center targetnoy therapy ( Site 1203)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>74956317427</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg City Polyclinic 117-endocrinology department ( Site 1201)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194358</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78124977332</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Astarta Clinic ( Site 1202)</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>199226</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78123372303</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria-UGC Endocrinologia y nutricion ( Site 1405)</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34951034016</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUS - Hospital Clinico Universitario ( Site 1403)</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34981951378</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron-Liver Unit - Department of Internal Medicine ( Site 1400)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932746140</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA-Gastroenterologia y Hepatologia ( Site 1402)</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34911917889</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Unidad de Ensayos Clínicos de Aparato Digestivo ( Site 1404)</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34955012065</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NATIONAL CHENG-KUNG UNI. HOSP.-Liver Research team of National Cheng Kung University Hospital ( Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886 6 235 3535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital ( Site 1501)</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>886223123456</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation-Linkou Branch-Division of hepatology, department of gastroenterology (</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+886-3-3281200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylül Üniversitesi-Endocrinology and Met. ( Site 1610)</name>
      <address>
        <city>Balçova</city>
        <state>Izmir</state>
        <zip>35330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0905055251150</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara University Department of Hematology, Clinical Research Unit ( Site 1603)</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0905335429317</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi-internal diseases ( Site 1602)</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>095332344232</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gazi Universitesi-gastroenterology ( Site 1605)</name>
      <address>
        <city>Ankara</city>
        <zip>06560</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0905053192257</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bezmialem Vakf Üniversitesi-Gastroenterology ( Site 1606)</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905323448718</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ukrainian Research Institute of Therapy ( Site 1704)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>310039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380677188896</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>L.T. Mala National Institute of Therapy of NAMS of Ukraine-Department of Aging Studies and Prevent</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380501699696</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poltova Oblast Clinical Hospital IM.M.V.Sklifosovskoho ( Site 1710)</name>
      <address>
        <city>Poltava</city>
        <state>Poltavska Oblast</state>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380532224277</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

